Literature DB >> 11978504

How predictive is PK/PD for antibacterial agents?

Niels Frimodt-Møller1.   

Abstract

The pharmacodynamic (PD) parameters most often used in studies of antibiotic effect include the following relationships between the antibiotic concentration curve in serum as a surrogate marker for the antibiotic concentration at the infection site, the peak/minimal inhibitory concentration (MIC) ratio, the area under the curve (AUC)/MIC ratio and the duration of time the concentration exceeds the MIC (T(>MIC)). The MIC plays an important role also as a PD marker, and its precision in this respect is discussed. The predictive role of T(>MIC) is important for drugs showing minimal concentration dependent effect such as the beta-lactam antibiotics, the macrolides and others. The time can be calculated as the chronological time measured or as the (cumulative) per cent of the dosing interval covered by the dose. Several clinical studies have confirmed this relationship. It can be deduced from experimental as well as clinical studies that there is a minimal effective time (MET), which needs to be covered by the antibiotic concentration at the site of infection in order to achieve cure. Dosing according to this MET will result in the least antibiotic needed for the shortest duration. In several cases a single dose will suffice to cover the MET. If this is not possible the antibiotic should be dosed in a way, that each dose will surpass the MIC for at least 40-50% of the dosing interval. For antibiotics with a clear concentration-dependent bacterial killing effect the most important pharmacokinetic/pharmacodynamic (PK/PD) index is the peak/MIC ratio (or the AUC/MIC ratio). This is the case for aminoglycosides and fluoroquinolones, and for both classes a peak/MIC ratio of at least 10 within the first 24 h of treatment has been shown to result in around 90% bacteriological as well as clinical cure. One consequence of clinical dosing has been the once-a-day (OD) dosing for aminoglycosides, which is the standard mode of therapy in many countries. Clinical studies in the field of antibacterial PD are still relatively scarce, and much information is needed to enable relevant dosing strategies for all types of antibiotics against all common infections and micro-organisms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11978504     DOI: 10.1016/s0924-8579(02)00029-8

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  25 in total

1.  Prediction of resistance development against drug combinations by collateral responses to component drugs.

Authors:  Christian Munck; Heidi K Gumpert; Annika I Nilsson Wallin; Harris H Wang; Morten O A Sommer
Journal:  Sci Transl Med       Date:  2014-11-12       Impact factor: 17.956

2.  Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.

Authors:  S Krasniqi; P Matzneller; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

3.  Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.

Authors:  Elisabet I Nielsen; Anders Viberg; Elisabeth Löwdin; Otto Cars; Mats O Karlsson; Marie Sandström
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

4.  Population pharmacokinetic and pharmacodynamic modeling of norvancomycin.

Authors:  J Zhang; Y Zhang; Y Shi; J Rui; J Yu; G Cao; J Wu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-09       Impact factor: 3.267

5.  Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.

Authors:  Dolores Santos Buelga; María del Mar Fernandez de Gatta; Emma V Herrera; Alfonso Dominguez-Gil; María José García
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

6.  Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.

Authors:  P Matzneller; S Krasniqi; M Kinzig; F Sörgel; S Hüttner; E Lackner; M Müller; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

Review 7.  Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis.

Authors:  Florian M E Wagenlehner; Wolfgang Weidner; Kurt G Naber
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  A Physiologically Based Pharmacokinetic Perspective on the Clinical Utility of Albumin-Based Dose Adjustments in Critically Ill Patients.

Authors:  Huybrecht T'jollyn; An Vermeulen; Jan Van Bocxlaer; Pieter Colin
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

Review 9.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  Effects of age on the pharmacokinetics of single dose sulfamethazine after intravenous administration in cattle.

Authors:  Eduardo E Baroni; Diego C Díaz; Eduardo Picco; Samanta Waxman; Casilda Rodríguez; Manuel I San Andrés; Juan C Boggio
Journal:  Vet Res Commun       Date:  2008-05-15       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.